ArticleClinical lipidology2013
Setting the course for apoAII: a port in sight?
Article in Clinical lipidology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Context-Dependent Effects of Apolipoprotein A2 on Lipid Metabolism and Atherogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Pleiotropic effects of apolipoprotein A-Ⅱ on high-density lipoprotein functionality, adipose tissue metabolic activity and plasma glucose homeostasis.Journal of biomedical research · 2019Article
- A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function.Obesity science & practice · 2019Review
- Proteomic analysis to identify candidate biomarkers associated with type 1 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- βDrug design, development and therapy · 2017Article
- Speciated High-Density Lipoprotein Biogenesis and Functionality.Current atherosclerosis reports · 2016Review
- High-Density Lipoproteins for Therapeutic Delivery Systems.Journal of materials chemistry. B · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
ApoAII, the second most abundant protein of the human plasma HDLs, was discovered nearly 50 years ago. Over the subsequent years, nearly 2000 studies - epidemiological, cell-based, biochemical, mouse and human - have attempted to unravel its role in human lipid metabolism. On the basis of these studies, apoAII has been described as an activator and inhibitor of various plasma activities, and as both pro- and anti-atherogenic. Here, we summarize the studies of apoAII, use the preponderance of evidence to propose that the apoAII compass can be reset towards an antiatherogenic course, and suggest ways to stay the course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.